European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory effects Phase III FIBRONEER™️trials demonstrated that nerandomilast effectively slows lung function decline in adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis […]